Avalyn Pharma (NASDAQ:AVLN) Trading Down 4.4% – Time to Sell?

Avalyn Pharma Inc. (NASDAQ:AVLN)’s stock price fell 4.4% during trading on Thursday . The company traded as low as $33.20 and last traded at $33.20. Approximately 42,641 shares changed hands during trading, a decline of 86% from the average session volume of 310,610 shares. The stock had previously closed at $34.71.

Analyst Ratings Changes

A number of analysts recently commented on AVLN shares. Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Weiss Ratings began coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Guggenheim began coverage on Avalyn Pharma in a report on Monday, May 25th. They set a “buy” rating and a $80.00 price objective for the company. Finally, Morgan Stanley raised their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Stock Down 4.5%

The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The firm has a market cap of $1.47 billion and a PE ratio of -1.45. The business has a 50 day simple moving average of $33.17.

Avalyn Pharma (NASDAQ:AVLN) last posted its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. On average, research analysts predict that Avalyn Pharma Inc. will post -3.81 earnings per share for the current year.

Institutional Trading of Avalyn Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Montanova Capital LLC acquired a new stake in Avalyn Pharma during the 2nd quarter worth approximately $82,402,000. Braidwell LP bought a new position in shares of Avalyn Pharma during the second quarter valued at $26,382,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma during the second quarter worth $1,321,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.